Abstract:Abstract The tumor microenvironment has a fundamental role in the escape phenomenon of cancerous cells from the immune surveillance, the immunological protective mechanisms of the host. These cells produce active substances that can bind to and stimulate the inhibitory immune checkpoints (CTLA-4, PD1 etc.) expressed on the cytotoxic T-lymphocytes and other immunocompetenT-cells, thus inhibiting the immune defense. The immune checkpoint inhibitors (ICIs), introduced in therapeutic use in 2011, are human or humanized monoclonal antibodies (mAbs) that block the immune checkpoints, and thus release the inhibition, restoring the antitumoral immune defense. After the description of their mechanism of action, the clinical applications of anti-CTLA-4 mAbs ipilimumab and tremelimumab, anti-PD1-antibodies nivolumab and pembrolizumab, and the anti-PD-L1-antibodies are presented. The ICIs are used mainly in inoperable and advanced tumors, but this fact is not a rigorous rule, and their therapeutic indications have been and will continue to expand. The next section summarizes new research directions that are also needed, because primary and adaptive resistance to ICIs exists, the latter developing during therapy. In an unselected population, ICIs are therapeutically efficient only in about 20-30% of patients, but these will be long-term survivors. Not rarely the therapeutic effect is preceded by a transient pseudoprogression. Tumors with high mutation burden (melanoma, lung, and bladder cancers) respond much better to ICI therapy, because they produce more neoantigens; this is the case in the “hot” tumors, too, because in these tumor-infiltrating immune cells are markedly present. Their application would require reliable predictive biomarkers, but there are few of them so far, e.g., investigation of PD-L1 expression, and diagnostic tests associated to ICIs. This first part of the review ends with problems regarding therapy resistance and their possible solutions.

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Tumor Immune Checkpoints and Their Associated Inhibitors

Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review

Immune checkpoint: The novel target for antitumor therapy

[Immune-checkpoints: the new anti-cancer immunotherapies]

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Therapeutic Development of Immune Checkpoint Inhibitors

Therapeutic importance, general and endocrine adverse effects of immune checkpoint inhibitors I: mechanism of action and therapeutic use

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Immune Checkpoint Inhibitor-Based Strategies For Synergistic Cancer Therapy

Metabolic Interventions Combined with CTLA-4 and PD-1/PD-L1 Blockade for the Treatment of Tumors: Mechanisms and Strategies.

Immune Checkpoint Blockade and Its Combination Therapy with Small-Molecule Inhibitors for Cancer Treatment

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC

Immune Checkpoints as Therapeutic Targets in Autoimmunity

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?